Now I have all the information I need. Let me produce the consolidated review.

## Summary

This paper introduces ComputAgeBench, a systematic benchmark for evaluating blood-based epigenetic aging clocks. The authors collect and harmonize 66 public DNA methylation datasets covering 19 aging-accelerating conditions across 9 disease categories, define four evaluation tasks (relative acceleration detection AA2, absolute acceleration detection AA1, chronological age accuracy, and prediction bias), and test 13 published clock models. The central methodological contribution is a principled, a priori definition of aging-accelerating conditions (AACs) based on reduced life expectancy, chronicity, and systemic manifestation, and a four-task design that separates biological sensitivity from confounding factors like prediction bias.

## Strengths

- **Unprecedented scale of harmonized data for clock validation**: The paper assembles 66 datasets spanning 19 conditions across 9 categories from >50 studies — substantially larger and more diverse than prior comparative studies (which are described as "small-scale" or limited to chronological age prediction). This directly addresses a gap identified in reviews calling for standardized validation resources.

- **Principled, a priori AAC selection criteria**: The paper defines three explicit criteria (decreased life expectancy, chronic, systemic) applied before any model evaluation (Section 3.1). This contrasts with ad-hoc disease selection in prior work and follows the recommendation by Moqri et al. (2024) that biomarker formulations be established "a priori." The appendix (Table A3) provides population-based evidence for each included condition.

- **Four-task design that separately addresses distinct failure modes**: The benchmark separates relative acceleration detection (AA2 — two-sample test), absolute acceleration detection (AA1 — one-sample test), chronological age accuracy, and systematic prediction bias. This decomposition is conceptually clean: the paper explicitly acknowledges that AA2 is the more rigorous task (Section 3.5: "Clearly, the first task (AA2) provides a more rigorous way to test aging clocks compared to AA1") and treats the cumulative score as a mechanism to salvage AA1 data while penalizing bias.

- **Quantitative demonstration of second-generation clock superiority on the cleanest task**: On the AA2 task (which avoids the AA1 confounds), the paper shows that second-generation clocks (PhenoAgeV2, GrimAgeV1/V2, PhenoAgeV1) consistently outperform first-generation clocks, reinforcing the growing consensus that mortality-trained predictors are more biologically relevant. All clocks fail on cardiovascular and metabolic diseases — an interesting negative finding.

## Weaknesses

### Fatal

None.

### Major

None.

### Minor

1. **The cumulative benchmarking score has a counterintuitive mathematical property (Section 3.6).** The penalty term in the cumulative score is `(1 - max(0, Med(Δ)) / Med(|Δ|))`. Because the denominator is Med(|Δ|) (a measure of prediction noise/variance), a noisier clock receives a *smaller* penalty for the same level of positive bias. This is counterintuitive for a bias-correction mechanism: noisy clocks should arguably be penalized *more*, not less. The paper acknowledges this is not optimal ("there could be a more optimal solution for the metric") and frames it as a starting point for community discussion. Since individual task results (AA2, AA1, bias) are all presented separately and readers can draw conclusions without the cumulative score, this does not invalidate the paper's findings — but the metric as presented in Table 1 should be interpreted with caution.

2. **The AAC panel's core assumption is acknowledged but not independently verified within the benchmark (Sections 3.1, 3.3, 5).** The benchmark tests whether clocks detect elevated epigenetic age acceleration in individuals with conditions that meet clinical AAC criteria. If a clock fails on a specific condition, the framework allows for multiple explanations (poor clock, strong covariate shift, or the condition not actually accelerating aging at the blood DNAm level). The paper does acknowledge this in the Discussion ("some datasets were evaluated incorrectly by all models... multidimensionality of aging"), and Table A3 in the appendix provides population-based evidence for each AAC's inclusion. However, the benchmark would be stronger with explicit external validation — e.g., citations to prior studies showing that each specific AAC elevates epigenetic age acceleration specifically (not just mortality), or meta-analyses confirming the effect. This is a structural limitation of the benchmark design rather than a fatal flaw, as the AACs are defined independently of clock performance.

3. **The dataset overlap check is stated but not described (Section 3.4).** The paper asserts: "We also ensured that no data in the benchmark was used to train any of the selected clocks." Given that multiple clocks (HorvathV1, Hannum, etc.) were trained on public GEO data and the benchmark itself draws 66 datasets from GEO, the risk of overlap is real. The paper does not describe *how* the overlap check was performed — whether by GEO ID matching, sample-level cross-referencing, or author inspection. This is a reporting gap that should be filled, even if briefly. (This is not a fatal issue because many of the benchmark datasets post-date the training data of the older clocks, but the claim needs substantiation.)

4. **The AA1 task remains susceptible to dataset-specific bias that the global bias measure does not fully capture (Sections 3.5, 3.6).** The paper's bias measure (Med(Δ) across all HC samples) is *global* — a clock could have zero global bias but positive bias on some datasets and negative bias on others, inflating AA1 scores on individual AAC-only datasets. The paper acknowledges this by positioning AA2 as "more rigorous" and treating AA1 as a secondary task that "allows including more data." This is a clear limitation explained by the authors, but readers should note that the cumulative score's global bias correction does not fully address dataset-specific systematic shifts.

### Trivial

- The paper's title "ComputAgeBench: Epigenetic Aging Clocks Benchmark" is slightly broader than the actual scope (blood/saliva/buccal DNAm on microarray platforms only). The abstract and methods are clear about the scope, but the title could be more precise. This is a minor framing issue.

## Nice-to-Haves

- **External validation of the AAC panel**: For a subset of conditions (e.g., HIV, type 2 diabetes) where independent data exist, the authors could cite meta-analyses or re-analyze prior publications to show these conditions are indeed associated with elevated epigenetic age acceleration specifically. This would strengthen the benchmark's credibility beyond the clinical AAC criteria.
- **Per-dataset bias analysis**: A sensitivity analysis showing how results change when datasets with strong batch effects (identified via the bias task) are removed would strengthen the paper.
- **Age distribution analysis**: An analysis of whether age differs between AAC and HC groups within each dataset, and whether AA2 results hold after correction for age, would be a useful addition.
- **Move AAC evidence summary to main text**: The population-based evidence for including each condition (currently in Table A3) would strengthen the main paper if summarized, even briefly.

## Removed Points

- **"The AAC panel is not independently validated" [critic's point 2, framed as structural/fatal]**: The paper references Table A3 for "population-based evidence for including each condition" and acknowledges the limitation in the Discussion (Section 5). The critic overstates this as a gold-standard circularity problem. The AACs are defined by independent clinical criteria, not by clock performance, so there is no logical circularity. The remaining kernel (that some conditions may not be detectable at the blood DNAm level) is acknowledged by the paper and retained as Minor weakness #2 above. The fatal framing is removed.
- **"Comparison to Biolearn is not clearly articulated"**: The paper explicitly distinguishes itself from Biolearn in Section 2.2, noting prior work relies on restricted-access mortality data and is "small-scale." This criticism reflects a misreading.
- **"Terminology: AAC vs disease"**: This is a philosophical preference, not a factual weakness. The paper defines AAC explicitly.
- **"AA1 task confounded by dataset-level covariate shift" [framed as a major gap]**: The paper explicitly states AA2 is "more rigorous" and designed to control covariate shifts (Section 3.5). The cumulative score is an acknowledged imperfect attempt to salvage AA1 data. This is already addressed. Retained as Minor weakness #4 above in reduced form.
- **"Missing appendix content / proofs"**: The parser strips appendix sections. These exist in the original submission.
- **"Code release not verifiable"**: The paper commits to code release post-blind review. This is standard for double-blind submissions and not a valid weakness.

## Novel Insights

None beyond the paper's own contributions. The reviews do not surface an insight about the paper that the paper does not already articulate itself.

## Suggestions

1. Describe the dataset-overlap verification method explicitly, even if briefly (e.g., GEO ID cross-referencing).
2. Tone down the framing of the cumulative benchmarking score as a definitive ranking metric, or add a caveat about the counterintuitive penalty property. Emphasize that the AA2 task (which avoids the score's complexity) is the primary rigorous evaluation.
3. Consider adding a brief summary of AAC evidence from Table A3 into the main text to strengthen the benchmark's credibility.
4. Add a per-dataset bias analysis or sensitivity analysis excluding high-bias datasets.

## Score and Decision

This is a solid benchmark paper with real contributions: a large harmonized dataset collection, a principled AAC selection methodology, and a clean four-task evaluation design. The weaknesses are minor — the cumulative score has an acknowledged imperfection, the AAC assumption is partially addressed, and there are reporting gaps — but none threaten the core contribution. The paper is transparent about its limitations and positions the cleaner AA2 task as the primary rigorous measure. The paper would be stronger with more detail on the dataset overlap check and external AAC validation, but in its current form it already provides substantial value to the community.

MY FINAL SCORE: <pineapple>7.5</pineapple>
MY FINAL DECISION: <orange>Accept</orange>